Abtique Platform (powered by HyperBind)

The Abtique Platform, powered by HyperBind, is EVQLV's in silico antibody design and discovery solution built for biopharmaceutical partners seeking to accelerate the development of therapeutic antibodies. By combining validated machine learning models with human oversight, Abtique transforms the pace, cost, and scale of drug development — replacing traditional, failure-prone discovery cycles with a faster, more precise computational approach.

Designed for teams working on challenging therapeutic targets, the platform enables de novo antibody design at a scale and speed that conventional wet-lab methods cannot match. EVQLV continuously expands its in silico capabilities to help partners redeploy precious resources toward the development of additional novel therapeutics.

Core Technology: HyperBind

• Sequence-driven antibody design platform that combines validated learning models with human oversight
• Capable of ranking tens of millions of antibody–antigen sequence pairs in under 48 hours
• Accelerates candidate discovery while maintaining reproducibility across studies
• Demonstrated ability to generate high-affinity antibodies against challenging targets, including GPCRs

Validated Performance

• In validation studies, HyperBind generated 20 high-affinity antibodies with KD ≤ 100 nM against a challenging GPCR target
• Three of those candidates achieved binding affinities below 10 nM
• Results demonstrate that sequence-based design can achieve binding strengths comparable to therapeutic-grade antibodies

Smarter, Faster Iterations

• Replaces traditional drug discovery cycles that rely on extensive guesswork, time-consuming engineering rounds, and repeated assays
• Minimizes guesswork by designing antibodies computationally rather than relying on conventional discovery methods
• Supports multi-parameter optimization that is both faster and customizable compared to legacy approaches
• Reduces the cost, risk, and failure rates associated with identifying lead-ready therapeutic candidates

The Abtique Platform is positioned as a partnership-oriented solution, enabling biopharmaceutical organizations to collaborate with EVQLV and leverage its in silico capabilities to pursue novel therapeutic antibody programs more efficiently and at greater scale.